Manoel Barros Bertolo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manoel Barros Bertolo has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Zoraida Sachetto
State University of Campinas, Brazil
4 shared publications - Alisson Pugliesi
Department of Orthopedics, Rheumatology, and Traumatology Universidade Estadual de Campinas Campinas Brazil
3 shared publications - Ivânio Alves Pereira
Universidade do Sul de Santa Catarina, Florianópolis, Brasil
3 shared publications - Percival Degrava Sampaio-Barros
Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
3 shared publications - Adriana Bruscato Bortoluzzo
Insper
2 shared publications - Ana Paula Toledo Del Rio
State University of Campinas, Brazil
2 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Are global definitions enough? Revisiting CDAI and SDAI remission cut-offs in Brazilian Rheumatoid Arthritis patients
Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which achieving remission is the most effective strategy to prevent progression and optimize long-term outcomes. The performance of commonly used disease activity indices has not been well validated in the Brazilian RA population. This study aimed to evaluate the agreement between CDAI/SDAI and the revised Boolean 2.0 remission criteria, which served as the reference standard, and to identify the most accurate CDAI and SDAI remission cut-offs in this population. Methods: We conducted a cross-sectional analysis of baseline data from a Brazilian Cohort study, which included 840 patients from 11 public hospitals in Brazil. Disease activity was assessed using DAS28-CRP, DAS28-ESR, SDAI, CDAI, and Boolean 1.0/2.0. Agreement was assessed using Cohen’s kappa, and optimal remission cut-offs were determined through ROC curve analysis. Results: The study population was predominantly female (89.8%), with a mean age of 57 years and a median disease duration of 12 years. DAS28-CRP showed the highest remission rate (39.2%), whereas Boolean 1.0 showed the lowest (15.1%). Strong agreement was found between Boolean 2.0, and both the SDAI (κ = 0.775) and CDAI (κ = 0.692). ROC analysis revealed that the most accurate remission cut-offs were SDAI ≤ 4.3 and CDAI ≤ 3.9, which increased remission detection by 5.9% and 6.2%, respectively. Conclusion: In our cohort, SDAI ≤ 4.3 and CDAI ≤ 3.9 were the values most closely aligned with Boolean 2.0 remission. These adjusted cut-offs may help minimize overtreatment in resource-limited settings. Prospective studies assessing function, radiographic progression, and quality of life are warranted to confirm their validity in the Brazilian population.
- 13 March 2026
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessAre global definitions enough? Revisiting CDAI and SDAI remission cut-offs in Brazilian Rheumatoid Arthritis patients
Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which achieving remission is the most effective strategy to prevent progression and optimize long-term outcomes. The performance of commonly used disease activity indices has not been well validated in the Brazilian RA population. This study aimed to evaluate the agreement between CDAI/SDAI and the revised Boolean 2.0 remission criteria, which served as the reference standard, and to identify the most accurate CDAI and SDAI remission cut-offs in this population. Methods: We conducted a cross-sectional analysis of baseline data from a Brazilian Cohort study, which included 840 patients from 11 public hospitals in Brazil. Disease activity was assessed using DAS28-CRP, DAS28-ESR, SDAI, CDAI, and Boolean 1.0/2.0. Agreement was assessed using Cohen’s kappa, and optimal remission cut-offs were determined through ROC curve analysis. Results: The study population was predominantly female (89.8%), with a mean age of 57 years and a median disease duration of 12 years. DAS28-CRP showed the highest remission rate (39.2%), whereas Boolean 1.0 showed the lowest (15.1%). Strong agreement was found between Boolean 2.0, and both the SDAI (κ = 0.775) and CDAI (κ = 0.692). ROC analysis revealed that the most accurate remission cut-offs were SDAI ≤ 4.3 and CDAI ≤ 3.9, which increased remission detection by 5.9% and 6.2%, respectively. Conclusion: In our cohort, SDAI ≤ 4.3 and CDAI ≤ 3.9 were the values most closely aligned with Boolean 2.0 remission. These adjusted cut-offs may help minimize overtreatment in resource-limited settings. Prospective studies assessing function, radiographic progression, and quality of life are warranted to confirm their validity in the Brazilian population.
- Open Access
- 6 November 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (1) , 32-34
Myocardial strain in rheumatoid arthritis without traditional cardiovascular risk factors: an exploratory analysis
- 6 November 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (1) , 32-34
Open AccessMyocardial strain in rheumatoid arthritis without traditional cardiovascular risk factors: an exploratory analysis
- Open Access
- 6 July 2023
- Published by Springer Nature in Advances in Rheumatology
- Vol. 63 (1) , 1-10
Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
Background: Our aim was to compare the efficacy of rituximab, tocilizumab, and abatacept in individuals with rheumatoid arthritis (RA) refractory to treatments with MTX or TNFi agents.Methods: We searched 6 databases until January 2023 for phase 2–4 RCTs evaluating patients with RA refractory to MTX or TNFi therapy treated with rituximab, abatacept, and tocilizumab (intervention arm) compared to controls. Study data were independently assessed by two investigators. The primary outcome was considered as achieving ACR70 response.Results: The meta-analysis included 19 RCTs, with 7,835 patients and a mean study duration of 1.2 years. Hazard ratios for achieving an ACR70 response at six months were not different among the bDMARDs, however, we found high heterogeneity. Three factors showing a critical imbalance among the bDMARD classes were identified: baseline HAQ score, study duration, and frequency of TNFi treatment in control arm. Multivariate meta-regression adjusted to these three factors were conducted for the relative risk (RR) for ACR70. Thus, heterogeneity was attenuated (I2 = 24%) and the explanatory power of the model increased (R2 = 85%). In this model, rituximab did not modify the chance of achieving an ACR70 response compared to abatacept (RR = 1.773, 95%CI 0.113–10.21,p = 0.765). In contrast, abatacept was associated with RR = 2.217 (95%CI 1.554–3.161,p < 0.001) for ACR70 compared to tocilizumab.Conclusion: We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.
- 6 July 2023
- Published by Springer Nature in Advances in Rheumatology
- Vol. 63 (1) , 1-10
Open AccessCompared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
Background: Our aim was to compare the efficacy of rituximab, tocilizumab, and abatacept in individuals with rheumatoid arthritis (RA) refractory to treatments with MTX or TNFi agents.Methods: We searched 6 databases until January 2023 for phase 2–4 RCTs evaluating patients with RA refractory to MTX or TNFi therapy treated with rituximab, abatacept, and tocilizumab (intervention arm) compared to controls. Study data were independently assessed by two investigators. The primary outcome was considered as achieving ACR70 response.Results: The meta-analysis included 19 RCTs, with 7,835 patients and a mean study duration of 1.2 years. Hazard ratios for achieving an ACR70 response at six months were not different among the bDMARDs, however, we found high heterogeneity. Three factors showing a critical imbalance among the bDMARD classes were identified: baseline HAQ score, study duration, and frequency of TNFi treatment in control arm. Multivariate meta-regression adjusted to these three factors were conducted for the relative risk (RR) for ACR70. Thus, heterogeneity was attenuated (I2 = 24%) and the explanatory power of the model increased (R2 = 85%). In this model, rituximab did not modify the chance of achieving an ACR70 response compared to abatacept (RR = 1.773, 95%CI 0.113–10.21,p = 0.765). In contrast, abatacept was associated with RR = 2.217 (95%CI 1.554–3.161,p < 0.001) for ACR70 compared to tocilizumab.Conclusion: We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.
- Open Access
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
MUSCULOSKELETAL MANIFESTATIONS OF PRIMARY HYPOPARATHYROIDISM
- 12 September 2022
- Published by Sociedade Brasileira de Reumatologia
Open AccessMUSCULOSKELETAL MANIFESTATIONS OF PRIMARY HYPOPARATHYROIDISM
- Open Access
- 2 September 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (19) , 5044-5053
Impaired repair properties of endothelial colony‐forming cells in patients with granulomatosis with polyangiitis
In patients with ANCA‐associated vasculitis, interactions between neutrophils and endothelial cells cause endothelial damage and imbalance. Endothelial colony‐forming cells (ECFCs) represent a cellular population of the endothelial lineage with proliferative capacity and vasoreparative properties. This study aimed to evaluate the angiogenic capacity of ECFCs of patients with granulomatosis with polyangiitis (GPA). The ECFCs of 13 patients with PR3‐positive GPA and 14 healthy controls were isolated and characterized using fluorescence‐activated cell sorting, capillary tube formation measurement, scratching assays and migration assays with and without plasma stimulation. Furthermore, three patients with active disease underwent post‐treatment recollection of ECFCs for longitudinal evaluation. The ECFCs from the patients and controls showed similar capillary structure formation. However, the ECFCs from the patients with inactive GPA exhibited early losses of angiogenic capacity. Impairments in the migration capacities of the ECFCs were also observed in patients with GPA and controls (12th h, p = 0.05). Incubation of ECFCs from patients with GPA in remission with plasma from healthy controls significantly decreased migration capacity (p = 0.0001). Longitudinal analysis revealed that treatment significantly lowered ECFC migration rates. This study revealed that ECFCs from the patients with PR3‐positive GPA in remission demonstrated early losses of tube formation and reduced migration capacity compared to those of the healthy controls, suggesting impairment of endothelial function.
- 2 September 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (19) , 5044-5053
Open AccessImpaired repair properties of endothelial colony‐forming cells in patients with granulomatosis with polyangiitis
In patients with ANCA‐associated vasculitis, interactions between neutrophils and endothelial cells cause endothelial damage and imbalance. Endothelial colony‐forming cells (ECFCs) represent a cellular population of the endothelial lineage with proliferative capacity and vasoreparative properties. This study aimed to evaluate the angiogenic capacity of ECFCs of patients with granulomatosis with polyangiitis (GPA). The ECFCs of 13 patients with PR3‐positive GPA and 14 healthy controls were isolated and characterized using fluorescence‐activated cell sorting, capillary tube formation measurement, scratching assays and migration assays with and without plasma stimulation. Furthermore, three patients with active disease underwent post‐treatment recollection of ECFCs for longitudinal evaluation. The ECFCs from the patients and controls showed similar capillary structure formation. However, the ECFCs from the patients with inactive GPA exhibited early losses of angiogenic capacity. Impairments in the migration capacities of the ECFCs were also observed in patients with GPA and controls (12th h, p = 0.05). Incubation of ECFCs from patients with GPA in remission with plasma from healthy controls significantly decreased migration capacity (p = 0.0001). Longitudinal analysis revealed that treatment significantly lowered ECFC migration rates. This study revealed that ECFCs from the patients with PR3‐positive GPA in remission demonstrated early losses of tube formation and reduced migration capacity compared to those of the healthy controls, suggesting impairment of endothelial function.
- Open Access
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 1354
AB0367 “the structural index score – sis” for rheumatoid foot and its relation to foot function, disability and physical performance tests
Background Feet are involved in 90%of Rheumatoid arthritis (RA) patients. The Structural Index Score(SIS) is a score that evaluates forefoot and rearfoot aspects. Although it has been used as a clinical tool to quantify foot deformities in RA, its relevance in clinical practice is uncertain. Objectives The aim of this study was to evaluate the relation of SIS with foot function, disability and physical performance tests in RA. Methods 104 RA patients of the outpatient clinic of Rheumatology/Unicamp were evaluated for SIS total, forefoot, rearfoot and its items (hallux valgus, metatarsalphalangeal (MTP) subluxation, 5th MTP exostosis, claw/hammer toe deformities, calcaneus varus/valgus angle, ankle range of motion (ARM) and planus/cavus foot deformity). Subjects also performed Foot Function Index-FFI, Health Assessment Questionnaire Disability Index-HAQ-DI, lower limb HAQ-LL-HAQ and physical tests: Berg Balance Scale-BBS, the Timed Up and Go-TUG and the 5-time sit down-to-stand up-SST5 tests.SIS items were compared with HAQ, LL-HAQ, FFI and physical tests through Kruskal- Wallis test and Spearman correlation coefficient with a 5% level of significance. Results SIS-Forefoot score did not correlate with any variables. Among the SIS-forefoot items, hallux valgus was associated with FFI-pain (p=0.007), FFI-disability(p=0.005)and FFI-total (p=0.016); MTP subluxation was weakly correlated with FFI-disability (rs=0.196) and 5th MTP exostosis was associated with FFI-pain(p=0.018). SIS-Total, SIS-Rearfoot and its associated and correlated items are shown in table 1. Conclusions It is not clear if the use of SIS may be related to function and disability in RA. Forefoot SIS did not show correlation although hallux valgus, MTP subluxation and 5th MTP exostosis may be related to foot function. Rearfoot SIS and its items seem to be most correlated with function and disability in RA. References [1] Kerry RH, et al. The foot in chronic rheumatoid arthritis:a continuing problem. The Foot1994;4:201–3. [2] Turner DE, et al. Biomechanics of the foot in rheumatoid arthritis:identifying abnormal function and the factors associated with localised disease’impact’.Clin Biomech2008;23(1):93–1003. [3] Platto MJ, et al. The relationship of pain and deformity of the rheumatoid foot to gait and an index of functional limitation. J Rheumatol1991;18:38–43. [4] Göksel Karatepe A, et al. Foot deformities in patients with rheumatoid arthritis: the relationship with foot functions. Int J Rheum Dis. 2010;13(2):158–63. Disclosure of Interest None declared
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 1354
Open AccessAB0367 “the structural index score – sis” for rheumatoid foot and its relation to foot function, disability and physical performance tests
Background Feet are involved in 90%of Rheumatoid arthritis (RA) patients. The Structural Index Score(SIS) is a score that evaluates forefoot and rearfoot aspects. Although it has been used as a clinical tool to quantify foot deformities in RA, its relevance in clinical practice is uncertain. Objectives The aim of this study was to evaluate the relation of SIS with foot function, disability and physical performance tests in RA. Methods 104 RA patients of the outpatient clinic of Rheumatology/Unicamp were evaluated for SIS total, forefoot, rearfoot and its items (hallux valgus, metatarsalphalangeal (MTP) subluxation, 5th MTP exostosis, claw/hammer toe deformities, calcaneus varus/valgus angle, ankle range of motion (ARM) and planus/cavus foot deformity). Subjects also performed Foot Function Index-FFI, Health Assessment Questionnaire Disability Index-HAQ-DI, lower limb HAQ-LL-HAQ and physical tests: Berg Balance Scale-BBS, the Timed Up and Go-TUG and the 5-time sit down-to-stand up-SST5 tests.SIS items were compared with HAQ, LL-HAQ, FFI and physical tests through Kruskal- Wallis test and Spearman correlation coefficient with a 5% level of significance. Results SIS-Forefoot score did not correlate with any variables. Among the SIS-forefoot items, hallux valgus was associated with FFI-pain (p=0.007), FFI-disability(p=0.005)and FFI-total (p=0.016); MTP subluxation was weakly correlated with FFI-disability (rs=0.196) and 5th MTP exostosis was associated with FFI-pain(p=0.018). SIS-Total, SIS-Rearfoot and its associated and correlated items are shown in table 1. Conclusions It is not clear if the use of SIS may be related to function and disability in RA. Forefoot SIS did not show correlation although hallux valgus, MTP subluxation and 5th MTP exostosis may be related to foot function. Rearfoot SIS and its items seem to be most correlated with function and disability in RA. References [1] Kerry RH, et al. The foot in chronic rheumatoid arthritis:a continuing problem. The Foot1994;4:201–3. [2] Turner DE, et al. Biomechanics of the foot in rheumatoid arthritis:identifying abnormal function and the factors associated with localised disease’impact’.Clin Biomech2008;23(1):93–1003. [3] Platto MJ, et al. The relationship of pain and deformity of the rheumatoid foot to gait and an index of functional limitation. J Rheumatol1991;18:38–43. [4] Göksel Karatepe A, et al. Foot deformities in patients with rheumatoid arthritis: the relationship with foot functions. Int J Rheum Dis. 2010;13(2):158–63. Disclosure of Interest None declared
- Open Access
- 1 January 2015
- Published by Springer Nature in Revista Brasileira de Reumatologia
- Vol. 55 (1) , 48-54
Avaliação do desempenho do BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) numa coorte brasileira de 1.492 pacientes com espondiloartrites: dados do Registro Brasileiro de Espondiloartrites (RBE)
To analyze the results of the application of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in a large series of Brazilian patients with the diagnosis of SpA and establish its correlations with specific variables into the group. A common protocol of investigation was prospectively applied to 1492 Brazilian patients classified as SpA according to the European Spondyoarthropathies Study Group (ESSG), attended at 29 referral centers of Rheumatology in Brazil. Clinical and demographic variables, and disease indices (BASDAI, Basfi, Basri, Mases, ASQol) were applicated. The total values of BASDAI were compared to the presence of the different variables. The mean score of BASDAI was 4.20 ± 2.38. The mean scores of BASDAI were higher in patients with the combined (axial + peripheral + entheseal) (4.54 ± 2.38) clinical presentation, compared to the pure axial (3.78 ± 2.27) or pure peripheral (4.00 ± 2.38) clinical presentations (p<0.001). BASDAI also presented higher scores associated with the female gender (p<0.001) and patients who did not practice exercises (p < 0.001). Regarding the axial component, higher values of BASDAI were significantly associated with inflammatory low back pain (p<0.049), alternating buttock pain (p<0.001), cervical pain (p<0.001) and hip involvement (p<0.001). There was also statistical association between BASDAI scores and the peripheral involvement, related to the lower (p=0.004) and upper limbs (p=0.025). The presence of enthesitis was also associated to higher scores of BASDAI (p=0.040). Positive HLA-B27 and the presence of cutaneous psoriasis, inflammatory bowel disease, uveitis and urethritis were not correlated with the mean scores of BASDAI. Lower scores of BASDAI were associated with the use of biologic agents (p<0.001). In this heterogeneous Brazilian series of SpA patients, BASDAI was able to demonstrate "disease activity" in patients with axial as well as peripheral disease.
- 1 January 2015
- Published by Springer Nature in Revista Brasileira de Reumatologia
- Vol. 55 (1) , 48-54
Open AccessAvaliação do desempenho do BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) numa coorte brasileira de 1.492 pacientes com espondiloartrites: dados do Registro Brasileiro de Espondiloartrites (RBE)
To analyze the results of the application of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in a large series of Brazilian patients with the diagnosis of SpA and establish its correlations with specific variables into the group. A common protocol of investigation was prospectively applied to 1492 Brazilian patients classified as SpA according to the European Spondyoarthropathies Study Group (ESSG), attended at 29 referral centers of Rheumatology in Brazil. Clinical and demographic variables, and disease indices (BASDAI, Basfi, Basri, Mases, ASQol) were applicated. The total values of BASDAI were compared to the presence of the different variables. The mean score of BASDAI was 4.20 ± 2.38. The mean scores of BASDAI were higher in patients with the combined (axial + peripheral + entheseal) (4.54 ± 2.38) clinical presentation, compared to the pure axial (3.78 ± 2.27) or pure peripheral (4.00 ± 2.38) clinical presentations (p<0.001). BASDAI also presented higher scores associated with the female gender (p<0.001) and patients who did not practice exercises (p < 0.001). Regarding the axial component, higher values of BASDAI were significantly associated with inflammatory low back pain (p<0.049), alternating buttock pain (p<0.001), cervical pain (p<0.001) and hip involvement (p<0.001). There was also statistical association between BASDAI scores and the peripheral involvement, related to the lower (p=0.004) and upper limbs (p=0.025). The presence of enthesitis was also associated to higher scores of BASDAI (p=0.040). Positive HLA-B27 and the presence of cutaneous psoriasis, inflammatory bowel disease, uveitis and urethritis were not correlated with the mean scores of BASDAI. Lower scores of BASDAI were associated with the use of biologic agents (p<0.001). In this heterogeneous Brazilian series of SpA patients, BASDAI was able to demonstrate "disease activity" in patients with axial as well as peripheral disease.
- Open Access
- 1 January 2014
- Published by Springer Nature in Revista Brasileira de Reumatologia
- Vol. 54 (1) , 33-37
Perfil do uso de drogas modificadoras de doença no Registro Brasileiro de Espondiloartrites
- 1 January 2014
- Published by Springer Nature in Revista Brasileira de Reumatologia
- Vol. 54 (1) , 33-37
Open AccessPerfil do uso de drogas modificadoras de doença no Registro Brasileiro de Espondiloartrites
- Open Access
- 1 January 2013
- Published by Hindawi Limited in Disease Markers
- Vol. 35 (2) , 73-78
HLA Markers for Poor Prognosis in Systemic Sclerosis Brazilian Patients
Objectives. The aim of this study was to evaluate human leukocyte antigen (HLA) involvement in the disease expression and poor prognostic clinical features (pulmonary fibrosis and pulmonary arterial hypertension) in patients diagnosed with systemic sclerosis (SSc) in a multiethnic population.Methods. SSc patients followed up between 2008 and 2011 were included, and clinical data were obtained through records review. Molecular HLA typing was performed (polymerase chain reaction amplification technique using specific primer sequences). The statistical analysis involved Fisher’s exact test and Pearson's corrected chi-square test.were considered significant. The delta method was used to estimate the variance of the prevalence ratio (PR).Results. A total of 141 patients (120 women and 21 men) with SSc were studied, including 33.3% with diffuse cutaneous SSc (dcSSc), 62.4% with limited cutaneous SSc (lcSSc), and 4.3% with sine scleroderma. Pulmonary fibrosis was present in 61 patients (43.3%), and the HLA-A*30 and DQB1*04 alleles were related to susceptibility. In contrast, the HLA-DRB1*01 and DQB1*05 alleles were protective. Pulmonary arterial hypertension was diagnosed in 19 patients (13.5%) and was associated with HLA-B*35 and C*04; in contrast, C*03 seemed to be protective.Conclusions. Our current study documents the association of some classes I and II HLA alleles with the most severe clinical manifestations in a multiethnic case series. Our findings differed slightly from the previous data in other populations.- 1 January 2013
- Published by Hindawi Limited in Disease Markers
- Vol. 35 (2) , 73-78
Open AccessHLA Markers for Poor Prognosis in Systemic Sclerosis Brazilian Patients
Objectives. The aim of this study was to evaluate human leukocyte antigen (HLA) involvement in the disease expression and poor prognostic clinical features (pulmonary fibrosis and pulmonary arterial hypertension) in patients diagnosed with systemic sclerosis (SSc) in a multiethnic population.Methods. SSc patients followed up between 2008 and 2011 were included, and clinical data were obtained through records review. Molecular HLA typing was performed (polymerase chain reaction amplification technique using specific primer sequences). The statistical analysis involved Fisher’s exact test and Pearson's corrected chi-square test.were considered significant. The delta method was used to estimate the variance of the prevalence ratio (PR).Results. A total of 141 patients (120 women and 21 men) with SSc were studied, including 33.3% with diffuse cutaneous SSc (dcSSc), 62.4% with limited cutaneous SSc (lcSSc), and 4.3% with sine scleroderma. Pulmonary fibrosis was present in 61 patients (43.3%), and the HLA-A*30 and DQB1*04 alleles were related to susceptibility. In contrast, the HLA-DRB1*01 and DQB1*05 alleles were protective. Pulmonary arterial hypertension was diagnosed in 19 patients (13.5%) and was associated with HLA-B*35 and C*04; in contrast, C*03 seemed to be protective.Conclusions. Our current study documents the association of some classes I and II HLA alleles with the most severe clinical manifestations in a multiethnic case series. Our findings differed slightly from the previous data in other populations.